Fresenius Medical Care AG & Co. KGaA  / Key word(s): Legal Matter

17.02.2016 23:17

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Bad Homburg, Germany - Fresenius Medical Care AG & Co. KGaA ("the company"
or "Fresenius Medical Care"), the world's largest provider of dialysis
products and services, today announced that Fresenius Medical Care North
America (FMCNA) has reached an agreement in principle with a committee
designated by the plaintiffs to resolve litigation in the United States
involving GranuFlo(R)/NaturaLyte(R).

Under the agreement in principle, the settlement amount would be $250
million, provided that 97% of all plaintiffs agree to the settlement by
July 2016 with the funding provided in August 2016. Insurers will fund the
settlement amount with $220 million.

Therefore, the company expects a pre-tax charge of $60 million from the
settlement and other costs to finalize this matter. This impact for the
company will be reflected in its 2015 numbers to be published on February
24, 2016.


---------------------------------------------------------------------------

Information and Explaination of the Issuer to this News:

For 2015 the company expects to report revenues of approximately $16.7
billion. Excluding the charge net of tax, the 2015 net income attributable
to shareholders should increase by approximately 2% over the prior year
period. On that basis the company expects to be in line with its financial
guidance for 2015.

The company's GranuFlo(R)/NaturaLyte(R) product at issue in the litigation
remains on the market and continues to be the market leader for dialysis
acid concentrates in the United States. There has been no change in the
composition of the product and it remains safe and effective when used and
prescribed as directed.

Fresenius Medical Care is the world's largest provider of products and
services for individuals with renal diseases of which more than 2.6 million
patients worldwide regularly undergo dialysis treatment. Through its
network of 3,402 dialysis clinics, Fresenius Medical Care provides dialysis
treatments for 290,250 patients around the globe. Fresenius Medical Care is
also the leading provider of dialysis products such as dialysis machines or
dialyzers. Along with the core business, the company focuses on expanding
the range of additional medical services in the field of care coordination.

For more information visit the company's website at
www.freseniusmedicalcare.com.

Disclaimer
This release contains forward-looking statements that are subject to
various risks and uncertainties. Actual results could differ materially
from those described in these forward-looking statements due to certain
factors, including changes in business, economic and competitive
conditions, regulatory reforms, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties are
detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the
U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co.
KGaA does not undertake any responsibility to update the forward-looking
statements in this release.

17.02.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Fresenius Medical Care AG & Co. KGaA
              Else-Kröner-Straße 1
              61352 Bad Homburg
              Germany
Phone:        +49 (0) 6172- 609 2525
Fax:          +49 (0) 6172- 609 2301
E-mail:       ir@fmc-ag.com
Internet:     www.fmc-ag.de
ISIN:         DE0005785802, DE0005785836, 
WKN:          578580, 578583
Indices:      DAX
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated
              Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
              Munich, Stuttgart; Terminbörse EUREX; NYSE
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------